Compare
Carlsmed, Inc. vs Shoulder Innovations, Inc. vs TriSalus Life Sciences, Inc. vs CVRx, Inc.
| Latest fiscal year | Carlsmed, Inc. CARL | Shoulder Innovations, Inc. SI | TriSalus Life Sciences, Inc. TLSI | CVRx, Inc. CVRX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $50.51M | $47.32M | $45.15M | $56.65M |
| Revenue growth (YoY) | +85.9% | +49.6% | +53.4% | +10.4% |
| Gross margin | 75.3% | 76.5% | 84.6% | 85.3% |
| Operating margin | -60.5% | -55.6% | -59.7% | -90.5% |
| Net margin | -58.7% | -85.3% | -86.9% | -94.1% |
| Net income | -$29.63M | -$40.36M | -$39.23M | -$53.31M |
| EPS (Diluted) | -$2.12 | -$4.65 | -$1.84 | -$2.04 |
| Operating cash flow | -$28.98M | -$28.61M | -$18.01M | -$40.17M |
| Free cash flow | -$29.62M | -$36.02M | -$18.93M | -$40.75M |
| Cash & equivalents | $85.79M | $26.87M | $20.44M | $75.71M |
| Total assets | $130.12M | $169.91M | $35.33M | $104.79M |
| Total liabilities | $31.25M | $29.16M | $69.19M | $65.47M |
| Shareholders' equity | $98.87M | $140.75M | -$33.86M | $39.32M |
| Return on year-end equity | -30.0% | -28.7% | n/a | -135.6% |
| Shares outstanding | 26.60M | 20.62M | 50.00M | 26.31M |
Revenue, most recent five fiscal years
| Fiscal year | Carlsmed, Inc. | Shoulder Innovations, Inc. | TriSalus Life Sciences, Inc. | CVRx, Inc. |
|---|---|---|---|---|
| Latest | $50.51M Ended 2025-12-31 | $47.32M Ended 2025-12-31 | $45.15M Ended 2025-12-31 | $56.65M Ended 2025-12-31 |
| 1 year earlier | $27.16M Ended 2024-12-31 | $31.62M Ended 2024-12-31 | $29.43M Ended 2024-12-31 | $51.29M Ended 2024-12-31 |
| 2 years earlier | n/a | n/a | $18.51M Ended 2023-12-31 | $39.30M Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | $12.40M Ended 2022-12-31 | $22.47M Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | n/a | $13.04M Ended 2021-12-31 |